Navigation Links
Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Date:11/1/2007

tion can be administered safely in this patient population. In the trial, no neuropathy greater than grade 1 has been observed in all patients treated, including four patients who received a cumulative picoplatin dose of greater than 900 mg/m2. The Company plans to present data from the Phase 1 trial at scientific meetings in 2008.

The platinum therapy oxaliplatin is an integral component of chemotherapy regimens which have become a standard treatment for metastatic CRC. The associated side effects, most notably, neuropathy, can significantly impair the quality of life of patients and limits the optimal use of oxaliplatin. According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, discontinuation of oxaliplatin from the FOLFOX regimen (in which oxaliplatin is given in combination with 5- fluorouracil and leucovorin) should be strongly considered after three months of therapy, or sooner if significant neurotoxicity develops.

Phase 2 Colorectal Cancer Trial Design

The Phase 2 trial will include approximately 100 patients with metastatic CRC randomized to either picoplatin (150 mg/m2) given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen or oxaliplatin in combination with 5-fluorouracil and leucovorin in the FOLFOX regimen. The trial will evaluate whether FOLPI demonstrates equivalent or better efficacy than FOLFOX without the substantial neurotoxicity associated with oxaliplatin. Efficacy and safety assessment will include objective tumor response, duration of response, progression-free survival, overall survival and assessment of peripheral neuropathy. The trial will be conducted at approximately 25 clinical sites and is expected to complete enrollment in the first half of 2008. The Company currently expects to have early tumor response data and long-term safety data in the first half of 2008 and intends to submit the data for presentation at scientific confere
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Novastem, a leader in regenerative ... in its study for ischemic stroke at Clinica ... ischemic strokes account for 87 percent of all ... in the study, entitled "Internal Research Protocol in ... Stem Cells and Intrathecal Administration of Neural Stem ...
(Date:12/24/2014)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... unaudited preliminary financial results for the first quarter ... 2015 Ended September 30, 2014 Financial Highlights: ... million in 1Q14 with gross margins improved to ...
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... Disability Employment Awareness Month marks the 20th ... magazine, the cutting-edge voice of disability culture in America. ... written and edited by staff and freelancers with disabilities, ... society, while simultaneously reflecting the vibrant world of disability-related ...
... (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) ... , announced today that new clinical studies presented this week ... in New Orleans, Louisiana, show Masimo noninvasive and ... to invasive blood tests for both healthy subjects and hospitalized ...
Cached Medicine Technology:Award-Winning Disability Lifestyle Magazine Celebrates 20 Years of Publication - And 20 Years of Employing People with Disabilities 2New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 2New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 3New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 4New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 5New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 6New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring Technology 7
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
(Date:12/25/2014)... 2014 AngelWeddingDress.com tries its best to ... realm. Today, the business has introduced its new collection ... dress promotion. , The new prom outfits are guaranteed ... dress lover. They are specially designed for 2015. Anyone ... dresses should visit its website before Jan. 26, 2015, ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
(Date:12/25/2014)... Carolina (PRWEB) December 25, 2014 ... Carolina Retirement Community, recently showed their generous spirit ... of the Catawba County Parenting Network- Grandparents Raising ... 10 children gathered around the largest Christmas tree ... open presents purchased by residents of the Abernethy ...
(Date:12/25/2014)... Parker & Sons, Inc. an industry leader ... quality regarding heating, cooling and plumbing services in the ... the “Queen of Clean” for impressive contractor services in ... over the years for providing outstanding quality customer service ... services for both homeowners and businesses. Linda Cobb, known ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3
... May ... ... Month, the perfect time to increase awareness about the importance of sun protection. According to ... the most common cancer in the United States but it is also one of the ...
... EDITOR,S PICK: Eliminating the source of asthma-causing immune molecules ... caused by inappropriate immune responses. Soluble IgE molecules, produced ... immune mediators of these diseases. Therapeutic targeting of IgE ... an effective treatment for moderate-to-severe allergic asthma. However, this ...
... ... Services to Dentists , ... Dallas, TX (PRWEB) May 10, 2010 -- Bold Ventures, a diversified holding ... had launched a new services company for the dental industry. The company, Dental Wealth Partners, ...
... uncontrolled cell division are the fundamental differences between cancer ... for these differences is that the biological clocks in ... in the fashion that they do in normal cells. ... the first experiment that has continuously monitored variations in ...
... and binge eating , MONDAY, May 10 (HealthDay News) ... the risk of impulse control disorders, such as problem ... In a new study that included 3,090 patients being ... the United States and Canada, the researchers found that ...
... side effects of popular proton pump inhibitors should not be ... inhibitors such as Prilosec and Nexium are among the most ... studies warn that the popular stomach acid reducers are showing ... an editorial in the May issue of the Archives ...
Cached Medicine News:Health News:The Incidence of Skin Cancer Has Reached Epidemic Levels 2Health News:The Incidence of Skin Cancer Has Reached Epidemic Levels 3Health News:The Incidence of Skin Cancer Has Reached Epidemic Levels 4Health News:JCI online early table of contents: May 17, 2010 2Health News:JCI online early table of contents: May 17, 2010 3Health News:JCI online early table of contents: May 17, 2010 4Health News:JCI online early table of contents: May 17, 2010 5Health News:JCI online early table of contents: May 17, 2010 6Health News:JCI online early table of contents: May 17, 2010 7Health News:JCI online early table of contents: May 17, 2010 8Health News:Bold Ventures Launches New Healthcare Business 2Health News:Bold Ventures Launches New Healthcare Business 3Health News:Bold Ventures Launches New Healthcare Business 4Health News:How cancer cells loose their (Circadian) rhythm 2Health News:Parkinson's Drugs Tied to Compulsive Behaviors 2Health News:Stomach Acid Drugs Come with Dangers, Studies Show 2Health News:Stomach Acid Drugs Come with Dangers, Studies Show 3Health News:Stomach Acid Drugs Come with Dangers, Studies Show 4
This fixed-volume digital micropipet is used to accurately measure and transfer 50 microliters of solution....
50L...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
Medicine Products: